Product Overview
Sermorelin 5 mg by British Dragon is supplied as a vial labeled with 5 mg of Sermorelin. Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), corresponding to the biologically active N-terminal portion of human GHRH. It stimulates endogenous growth hormone secretion through the pituitary rather than directly supplying HGH.
Product Class
Sermorelin belongs to the GHRH analogue / growth hormone secretagogue class. It acts through GHRH receptors and the endogenous GH/IGF-1 axis. It is a peptide rather than an anabolic steroid, SARM or androgen.
Indications
Sermorelin acetate was historically marketed as Geref for evaluation and treatment of certain growth-hormone-related disorders, including pediatric growth failure associated with inadequate endogenous GH secretion. Those pharmaceutical products were subsequently discontinued. Contemporary interest also includes GH-axis, body-composition, recovery and healthy-aging settings, but these should not be presented as established approved indications.
Mechanism of Action
Sermorelin binds GHRH receptors in the anterior pituitary, stimulating synthesis and pulsatile secretion of endogenous growth hormone. GH subsequently promotes hepatic and peripheral production of IGF-1. Because the peptide works upstream of the pituitary, its effects depend on a functioning endogenous GH secretory system.
Potential Benefits
The primary pharmacologic effect is stimulation of endogenous GH secretion with downstream IGF-1 activity. This has generated interest in growth, body composition, sleep, recovery and tissue metabolism. However, evidence supporting anti-aging or athletic-performance applications is substantially less established than historical endocrine applications.
Synergy & Stacking
Ipamorelin is frequently discussed with Sermorelin because the compounds stimulate GH through complementary receptors. Sermorelin activates the GHRH receptor, while Ipamorelin acts primarily through the ghrelin/GHS-R1a receptor. This provides a pharmacologic rationale for combined GH-secretagogue research but does not establish an approved combination protocol.
CJC-1295 and Tesamorelin also target GHRH signaling and therefore have greater mechanistic overlap with Sermorelin. Somatropin (HGH) differs fundamentally because it directly supplies recombinant growth hormone instead of stimulating pituitary release.
HRT/TRT Application
Sermorelin is not testosterone replacement therapy. It neither supplies Testosterone nor activates androgen receptors. It is sometimes discussed as part of broader hormone-management programs, but its pharmacologic target is the GH/IGF-1 axis rather than the hypothalamic-pituitary-gonadal axis.
Dosing and Use
The British Dragon product is labeled as containing 5 mg per vial. Historical pharmaceutical Sermorelin products had indication-specific medical dosing, but this does not establish a standardized regimen for independently supplied Sermorelin used for recovery, body composition or anti-aging purposes. The 5 mg designation therefore describes stated vial content rather than a recommended single administration or treatment schedule.
Female Use
Sermorelin is non-androgenic and is not expected to produce anabolic-steroid-type virilization. However, the absence of androgenic activity does not establish safety during pregnancy or breastfeeding, and these settings require separate medical consideration.
Comparative Analysis
Sermorelin vs Ipamorelin: Sermorelin activates GHRH receptors, whereas Ipamorelin activates GHS-R1a/ghrelin receptors. Both ultimately stimulate endogenous GH release through different upstream mechanisms.
Sermorelin vs CJC-1295: Both are GHRH-related peptides. CJC-1295 was designed for prolonged activity, whereas Sermorelin represents the shorter biologically active GHRH fragment.
Sermorelin vs Tesamorelin: Both stimulate GHRH receptors, but Tesamorelin has an established current pharmaceutical indication for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
Sermorelin vs HGH: Sermorelin stimulates the pituitary to produce endogenous GH; Somatropin directly supplies recombinant human growth hormone.
Sermorelin vs MK-677: Sermorelin is a peptide GHRH analogue, whereas Ibutamoren (MK-677) is an orally active non-peptide GHS-R1a agonist.
Conclusion
Sermorelin 5 mg by British Dragon is a GHRH analogue designed to stimulate endogenous growth hormone secretion and downstream IGF-1 signaling. Its pituitary mechanism distinguishes it from direct Somatropin administration and from GHS-R1a agonists such as Ipamorelin. Sermorelin has a historical pharmaceutical background in GH-related medicine, while contemporary non-approved applications remain less established. The stated 5 mg vial strength does not constitute a recommended therapeutic dose.
Sermorelin 5 mg FAQ
What is Sermorelin?
Sermorelin is a synthetic GHRH analogue that stimulates the pituitary to release endogenous growth hormone.
Is Sermorelin the same as HGH?
No. HGH directly supplies growth hormone, while Sermorelin stimulates the body's own GH secretion.
Does Sermorelin increase IGF-1?
By stimulating endogenous GH, Sermorelin can increase downstream IGF-1 production. The magnitude of response depends on individual pituitary and endocrine function.
Why are Sermorelin and Ipamorelin compared?
Both stimulate endogenous GH, but through different receptors: Sermorelin through GHRH receptors and Ipamorelin primarily through GHS-R1a.
Is Sermorelin the same as Tesamorelin?
No. Both are GHRH analogues, but they differ structurally, pharmacologically and in their regulatory and clinical histories.
